These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 1828266)
1. The effect of the calcium antagonist, isradipine, on working capacity, pulmonary function, morbidity and survival rate in patients with severe chronic obstructive pulmonary disease (COPD): a randomized, double-blind, placebo-controlled study. Galløe AM; Graudal N; Petersen JR; Leth P; Galløe M J Intern Med; 1991 May; 229(5):447-52. PubMed ID: 1828266 [TBL] [Abstract][Full Text] [Related]
2. [Severe obstructive lung disease. The effect of the calcium antagonist isradipine on working capacity, pulmonary function, morbidity and survival]. Petersen JR; Galløe AM; Graudal NA; Galløe M Ugeskr Laeger; 1993 Aug; 155(34):2612-5. PubMed ID: 8212369 [TBL] [Abstract][Full Text] [Related]
3. Atrial natriuretic peptide (ANP) in chronic obstructive pulmonary disease (COPD): the relationship between plasma ANP and lung function. Effects of exercise and of the calcium antagonist, isradipine, on plasma ANP. A randomised, double-blind, placebo-controlled study. Graudal N; Galløe AM; Storm T; Thamsborg G; Christensen HR Horm Metab Res; 1992 Mar; 24(3):130-3. PubMed ID: 1533606 [TBL] [Abstract][Full Text] [Related]
4. Erythropoietin in chronic obstructive pulmonary disease. Relationship between serum erythropoietin, blood hemoglobin and lung function--effect of the calcium antagonist isradipine on serum erythropoietin. Graudal N; Galløe AM; Nielsen OJ Respiration; 1991; 58(3-4):141-4. PubMed ID: 1836066 [TBL] [Abstract][Full Text] [Related]
5. No effect of the calcium antagonist, isradipine, on plasma catecholamines in irreversible chronic obstructive pulmonary disease (COPD). A randomized, double-blind, placebo-controlled study. Graudal NA; Galløe AM; Plum I; Milman N; Clausen JO Pulm Pharmacol; 1995; 8(2-3):131-5. PubMed ID: 8820252 [TBL] [Abstract][Full Text] [Related]
6. Calcium antagonists as first-line antihypertensive agents: a placebo-controlled, comparative trial of isradipine and nifedipine. Welzel D; Burger KJ; Weidinger G J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S70-4. PubMed ID: 1695308 [TBL] [Abstract][Full Text] [Related]
7. Effects of the calcium antagonist, isradipine, and nifedipine on resting and exercise haemodynamics and the neurohumoral system in patients with stable chronic angina. Mitrovic V; Rieckmann C; Kornecki P; Burger KJ; Welzel D; Schlepper M Eur Heart J; 1990 May; 11(5):454-61. PubMed ID: 2141313 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of the new calcium antagonist isradipine in essential hypertension. Kirch W; Burger KJ; Weidinger G; Welzel D J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S55-9. PubMed ID: 1695304 [TBL] [Abstract][Full Text] [Related]
9. [Electrophysiologic effects of the calcium antagonist isradipine, a double-blind placebo controlled study]. Kühlkamp V; Mayer F; Mauser M; Haasis R; Seipel L Z Kardiol; 1990 Jun; 79(6):436-40. PubMed ID: 2143045 [TBL] [Abstract][Full Text] [Related]
10. Central hemodynamics and brachial artery compliance during therapy with isradipine, a new calcium antagonist. Andersson OK; Persson B; Widgren BR; Wysocki M J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S87-9. PubMed ID: 1695312 [TBL] [Abstract][Full Text] [Related]
11. The calcium antagonist isradipine in the therapy of hypertension. A double-blind crossover comparison with nifedipine. Welzel D; Burger KJ Drugs; 1990; 40 Suppl 2():60-4. PubMed ID: 2150644 [TBL] [Abstract][Full Text] [Related]
12. Long-term renal effects of isradipine, a calcium entry blocker, in essential hypertension. Persson B; Wysocki M; Andersson OK J Cardiovasc Pharmacol; 1989 Jul; 14(1):22-4. PubMed ID: 2475710 [TBL] [Abstract][Full Text] [Related]
13. Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type II diabetes mellitus. Klauser R; Speiser P; Gisinger C; Schernthaner G; Prager R J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S93-6. PubMed ID: 1695314 [TBL] [Abstract][Full Text] [Related]
14. Hemodynamic study of short- and long-term isradipine treatment in patients with chronic ischemic congestive heart failure. McGrath BP; Newman R; Older P Am J Med; 1989 Apr; 86(4A):75-80. PubMed ID: 2523660 [TBL] [Abstract][Full Text] [Related]
15. Isotonic and isometric responses of blood pressure and heart rate in mild to moderate hypertension with isradipine and propranolol. Cantor A; Cristal N J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S76-8. PubMed ID: 1695309 [TBL] [Abstract][Full Text] [Related]
16. Additive effect of isradipine in combination with captopril in hypertensive patients. Eggertsen R; Svensson A; Dahlöf B; Hansson L Am J Med; 1989 Apr; 86(4A):124-6. PubMed ID: 2523647 [TBL] [Abstract][Full Text] [Related]
17. Electrophysiologic effects of the calcium antagonist isradipine, a double-blind placebo-controlled study. Kühlkamp V; Maier F; Seipel L Int J Cardiol; 1991 Feb; 30(2):215-20. PubMed ID: 1826285 [TBL] [Abstract][Full Text] [Related]
18. Multicenter evaluation of the safety and efficacy of isradipine in hypertension. The Italian-Belgian Isradipine Study Group. Am J Med; 1989 Apr; 86(4A):94-7. PubMed ID: 2523664 [TBL] [Abstract][Full Text] [Related]
19. Antihypertensive activity of isradipine in humans: a new dihydropyridine calcium channel antagonist. Nelson EB; Pool JL; Taylor AA Clin Pharmacol Ther; 1986 Dec; 40(6):694-7. PubMed ID: 2946507 [TBL] [Abstract][Full Text] [Related]
20. The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study. Leppert J; Jonasson T; Nilsson H; Ringqvist I Cardiovasc Drugs Ther; 1989 Jun; 3(3):397-401. PubMed ID: 2535054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]